- What are the market growth factors?
- Which segment provides the most opportunity for growth?
- Who are the leading vendors operating in this market?
Immunoassay Market Growth Factors -
• Technological advancements in immunoassay instruments and introduction of novel automated systems.
• Increasing incidence of chronic and infectious diseases.
• Growth in the biotechnology and bio-pharmaceutical industries.
• Increasing adoption of POC testing products.
Global market size -
The Immunoassay Market is expected to reach $27.15 Billion by 2023 from $20.19 Billion in 2018, at a CAGR of 6.1%.
Leading Segments -
•By platform, this market is classified into CLIAs, radioimmunoassays (RIAs), colorimetric immunoassays (CIS), fluorescence immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the largest share of the immunoassays market in 2017.
•On the basis of technology, the immunoassay market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment accounted for the largest share of the immunoassays market in 2017.
•On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services. In 2017, the reagents and kits segment accounted for the largest share of the immunoassays market.
Get more details, Download PDF Brochure Here
Top Players -
The immunoassays market is consolidated in nature due to the presence of a large number of players. Key players in the market include Abbott Laboratories (US), Roche (Switzerland), Siemens (Germany), Danaher Corporation (US), DiaSorin (OTCPK:ITALY), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Merck (Germany), Agilent Technologies (US), Quidel Corporation (US), PerkinElmer (US), Mindray (CHINA), and Bio-Techne Corporation (US).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.